Hyloris reinforces it’s Board of Directors with the nomination of Chris Buyse
New CFO to be appointed in early 2021, Stijn Van Rompay to act as interim CFO
Liège, Belgium – 1 December 2020: Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, is pleased to announce the nomination of Chris Buyse as independent Board member.
Chris Buyse brings considerable experience to Hyloris, with more than 30 years of international expertise across the healthcare sector. He is currently Managing Director of Fund+, the largest Belgian life sciences-dedicated venture capital fund. Chris holds a Masters degree in applied economic sciences from the University of Antwerp, and an MBA from the Vlerick School of Management in Ghent. He currently serves as member of the board of directors of several European companies listed on Nasdaq and Euronext, including iTeos Therapeutics, Celyad and Inventiva Pharma. Chris is also a Director of the Francqui Foundation, among other private mandates.
Commenting on his appointment, Chris Buyse said: “Hyloris is a company with the unique potential to add value to the healthcare system through its diverse and promising product portfolio. The Company is fully engaged to accelerate this strong portfolio towards approval and to deliver product candidates to market, making this an ideal time to join the Company’s Board of Directors and lend my experience at this exciting time.”
Chris’s mandate will be proposed for approval at the Company’s next Shareholder meeting. Until then, Chris will attend Company meetings as an observer. Chris will also be part of the audit committee.
Hyloris also announces that the temporary mandate of the Company’s acting Chief Financial Officer Astrid Heiremans ended on November 30. Stijn Van Rompay, CEO, will act as interim CFO until a new appointment is made, which is expected to occur during the first quarter of 2021.
Stijn Van Rompay, Chief Executive Officer and co-founder of Hyloris, commented: “I am pleased to welcome Chris to our Board of Directors. Chris brings outstanding experience to the role from his years in current and previous positions at listed European healthcare companies, and as the Managing Director of Fund+ he has shown his expertise in strategy and healthcare finance. I look forward very much to working with him. Over the last few months we have also strengthened the management team with a Chief Operating Officer, a head of formulations and a head market access. Finally, I’d like to thank Astrid Heiremans for her work as acting Chief Financial Officer of Hyloris. Astrid has been a pleasure to work with, and we wish her the best in her future endeavours.”
-Ends-
For more information, please contact:
Hyloris Pharmaceuticals
Stijn Van Rompay, CEO
+32 (0)4 346 02 07
contact@hyloris.com
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Taiana De Ruyck Soares
+44 20 3709 5700
hyloris@consilium-comms.com
About Hyloris Pharmaceuticals SA
Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris’ portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company’s partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company’s wider portfolio. Read more at www.hyloris.com. Hyloris stands for “high yield, lower risk” and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
Attachment
